Will weight loss drugs eat into supermarkets’ profits?

The skyrocketing demand for weight loss medications like Ozempic could temper shoppers’ appetites at our major supermarkets, Morgan Stanley says The Danish maker of GLP-1 receptor antagonists Ozempic and Wegovy, Novo Nordisk, reported sales of more than US$33.7bn in 2023, with forecasts suggesting continued, strong growth. In a note to investors, Morgan Stanley indicated the